May 01, 2013 10:00 ET

US-Russian Initiative in Life Science Cooperation

The Moscow Institute of Physics and Technology and the University of Wisconsin Announce a Non-Exclusive Consortium Developing Innovative Therapeutics Aimed at Improvement of Human and Animal Health

WASHINGTON, DC--(Marketwired - May 1, 2013) - The Moscow Institute of Physics and Technology Biopharmaceutical cluster "Northern" (BPCN@MIPT), the Wisconsin Technology Innovation Initiative, Inc. (Wi2) (formed to support the University of Wisconsin School of Medicine and Public Health), and ChemDiv Research Institute announced the signing of a Memorandum of Understanding (MOU) to form a non-exclusive consortium developing innovative therapeutics aimed at improvement of human and animal health. The official signing ceremony was held at the U.S.-Russia Innovation Working Group Meeting with the participation of Vladislav Surkov, Deputy Prime Minister of the Russian Federation; Robert D. Hormats, Under-Secretary for Economic Growth, Energy and the Environment of the USA; Oleg Fomichev, Deputy Minister of Economic Development of the Russian Federation; and others.

The overall aim of this Research and Development consortium is to jointly develop and market molecules, biological materials, medical devices, diagnostics, and other technologies and data resulting from Wi2, BPCN@MIPT and ChemDiv technologies. These platforms may include specialized training of research and clinical personnel, software programs and databases for digital healthcare.

Wi2 is a one of a kind non-profit organization formed to facilitate the translation of innovations into applied uses. The work of Wi2 is done in collaboration with the private sector, the University of Wisconsin-Madison, and other institutions nationally and internationally.

In accordance with the agreement terms, Wi2 will provide access to technologies in the fields of cancer, neurodegenerative diseases, and metabolic diseases, and will facilitate the transition of innovative technology developed at the University of Wisconsin into the marketplace. Wi2 will organize and finance a Translational Development Team (TDT) for each research platform through contributions by the other parties, grants obtained by Wi2, and, in the longer term, royalties derived from licensing of technologies resulting for the pre-commercialization efforts.

BPCN@MIPT provides access to technologies in the fields of biomed engineering and biophysics and innovative pharmaceuticals development. BPCN@MIPT also provides technological platforms and access to a highly diverse group of researchers of Moscow Institute of Physics and Technology (MIPT) and other cluster members including biophysicists, chemists, biochemists as well as computational scientists, advancing the interdisciplinary field of physics and the biophysics of excitable and self-organizing systems.

ChemDiv Research Institute, as a global CRO with 20 years experience in the life science industry, is a leading provider of integrated services to major pharmaceutical and biotech companies. ChemDiv grants access to its proprietary technologies such as protein engineering, production, structural biology and structure-based drug discovery, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK and multiple in vivo efficacy/toxicology models.

BPCN@MIPT and ChemDiv will jointly promote the collaborative platforms to a pre-approved set of global partners (including major pharmaceutical and biotechnology companies).

"We are very enthusiastic about this partnership. It is important to us to build and leverage international networks in order to be on the frontier of research, education, and innovation," said Oleg Korzinov, Executive Director of BPCN@MIPT. "Now, building this subsequent three way relationship with ChemDiv and Wi2 is of exceptional value due to their unique expertise and high profile. We are confident that this is the start of a strong and synergistic collaboration that will yield novel technologies and treatments for diseases with unmet medical needs."

Richard L Moss, PhD, U.W. Professor and Chief Scientific Officer of Wi2: "We are delighted with the new partnership for the opportunities it provides in the commercialization of innovative platform technologies originating from the School of Medicine and Public Health (University of Wisconsin), from our consortium partners, and elsewhere. Global outreach and public-private partnerships have the potential to promote the translation of discoveries from the laboratory to clinical care. This agreement promises to accelerate translation and address the needs of rapidly growing markets. The Moscow Institute of Physics and Technology is a world-class research institution in Russia and a strong ally in commercialization, with advanced capabilities in infrastructure, fundamental expertise, and essential human resources in research and development. We are also very excited about our private partner, ChemDiv, which is leading CRO focused on developing pharmaceutical in Russia."

Contact Information

  • Contact for media:
    Elena Surina
    PR Director, Biopharmaceutical cluster "Northern"
    E-mail: Email Contact